EC Neurology

Review Article Volume 16 Issue 9 - 2024

The Role of the Endocannabinoid System in Neuroprotection: Mechanisms and Therapeutic Potential

Nemer Mohammad Ali1* and Reham Kharmah2

1NKW Neurologische Klinik Westend in Bad Wildungen, Assisstenzarzt Neurologie, Department of Medicine, Misr University for Science and Technology, Egypt

2NKW Neurologische Klinik Westend in Bad Wildungen, Assisstenzarzt Neurologie, Department of Medicine, Misr University for Science and Technology, Egypt

*Corresponding Author: Nemer Mohammad Ali, NKW Neurologische Klinik Westend in Bad Wildungen, Assisstenzarzt Neurologie, Department of Medicine, Misr University for Science and Technology, Egypt.
Received: August 12, 2024; Published: September 04, 2024



The endocannabinoid system (ECS) regulates vital functions such as mood, immune response, and pain through cannabinoid receptors (CB1, CB2), endocannabinoids, and associated enzymes. In this discussion, we explore how endocannabinoids play a crucial role in neuroprotection, offering therapeutic potential for neurodegenerative diseases like Alzheimer's and Parkinson's through their anti-inflammatory, antioxidant, and neurogenic effects. Targeting the ECS with cannabinoids or enzyme inhibitors shows promise as a treatment strategy for these conditions.

 Keywords: Endocannabinoid System (ECS); Cannabinoid Receptors (CB1, CB2); Neuroprotection

  1. Battista N., et al. “The endocannabinoid system: an overview”. Frontiers in Behavioral Neuroscience 6 (2012): 9.
  2. Watkins BA. “Endocannabinoids, exercise, pain, and a path to health with aging”. Molecular Aspects of Medicine 64 (2018): 68-78.
  3. Alharthi NS. “Endocannabinoid system components: A crucial role in regulation of disease”. Journal of Advanced Pharmacy Education and Research3 (2022): 72-81.
  4. Lu HC and K Mackie. “Review of the endocannabinoid system”. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging6 (2021): 607-615.
  5. Svíženská I., et al. “Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures-a short review”. Pharmacology Biochemistry and Behavior4 (2008): 501-511.
  6. Onaivi ES., et al. “Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain”. Annals of the New York Academy of Sciences1 (2006): 514-536.
  7. Devane WA., et al. “Isolation and structure of a brain constituent that binds to the cannabinoid receptor”. Science5090 (1992): 1946-1949.
  8. Scherma M., et al. “Brain activity of anandamide: a rewarding bliss?” Acta Pharmacologica Sinica3 (2019): 309-323.
  9. Cabral GA., et al. “Endocannabinoids and the immune system in health and disease”. Endocannabinoids 231 (2015): 185-211.
  10. Basavarajappa BS. “Critical enzymes involved in endocannabinoid metabolism”. Protein and Peptide Letters3 (2007): 237-246.
  11. Bisogno T. “Endogenous cannabinoids: structure and metabolism”. Journal of Neuroendocrinology1 (2008): 1-9.
  12. Jain T., et al. “Diacylglycerol lipaseα (DAGLα) and DAGLβ cooperatively regulate the production of 2-arachidonoyl glycerol in autaptic hippocampal neurons”. Molecular Pharmacology2 (2013): 296-302.
  13. Deutsch DG. “A personal retrospective: elevating anandamide (AEA) by targeting fatty acid amide hydrolase (FAAH) and the fatty acid binding proteins (FABPs)”. Frontiers in Pharmacology 7 (2016): 370.
  14. Pan B., et al. “Blockade of 2-AG hydrolysis by selective monoacylglycerol lipase inhibitor JZL184 enhances retrograde endocannabinoid signaling”. Journal of Pharmacology and Experimental Therapeutics2 (2009): 591-597.
  15. Bermudez-Silva FJ., et al. “The role of the endocannabinoid system in the neuroendocrine regulation of energy balance”. Journal of Psychopharmacology1 (2012): 114-124.
  16. Woods SC. “The endocannabinoid system: mechanisms behind metabolic homeostasis and imbalance”. The American Journal of Medicine2 (2007): S9-S17.
  17. Lowe H., et al. “The endocannabinoid system: a potential target for the treatment of various diseases”. International Journal of Molecular Sciences17 (2021): 9472.
  18. Donvito G., et al. “The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain”. Neuropsychopharmacology1 (2018): 52-79.
  19. Bouchet CA and SL Ingram. “Cannabinoids in the descending pain modulatory circuit: Role in inflammation”. Pharmacology and Therapeutics 209 (2020): 107495.
  20. Mahalakshmi B., et al. “Possible neuroprotective mechanisms of physical exercise in neurodegeneration”. International Journal of Molecular Sciences16 (2020): 5895.
  21. Fague L., et al. “The basic science of optic nerve regeneration”. Annals of Translational Medicine15 (2021): 1276.
  22. Fumia A., et al. “Role of nutraceuticals on neurodegenerative diseases: Neuroprotective and immunomodulant activity”. Natural Product Research22 (2022): 5916-5933.
  23. Evans JA., et al. “Neuroprotective effects and therapeutic potential of the citrus flavonoid hesperetin in neurodegenerative diseases”. Nutrients11 (2022): 2228.
  24. Mohd Sairazi NS and K Sirajudeen. “Natural products and their bioactive compounds: neuroprotective potentials against neurodegenerative diseases”. Evidence‐Based Complementary and Alternative Medicine (2020): 6565396.
  25. Krishnamurthy PT., et al. “Neuroprotective approaches to halt Parkinson's disease progression”. Neurochemistry International 158 (2022): 105380.
  26. Kempuraj D., et al. “Neuroprotective effects of flavone luteolin in neuroinflammation and neurotrauma”. Biofactors2 (2021): 190-197.
  27. Marogianni C., et al. “Neurodegeneration and inflammation-an interesting interplay in Parkinson’s disease”. International Journal of Molecular Sciences22 (2020): 8421.
  28. Kasindi, A., et al. “Glatiramer acetate immunomodulation: evidence of neuroprotection and cognitive preservation”. Cells9 (2022): 1578.
  29. Rathod, S.S., et al. “Neuroinflammation in the central nervous system: Exploring the evolving influence of endocannabinoid system”. Biomedicines10 (2023): 2642.
  30. D Skaper S. “Mast cell-glia dialogue in chronic pain and neuropathic pain: blood-brain barrier implications”. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders)9 (2016): 1072-1078.
  31. Frasca D., et al. “Aging, obesity, and inflammatory age-related diseases”. Frontiers in Immunology 8 (2017): 1745.
  32. Young AP and EM Denovan-Wright. “The dynamic role of microglia and the endocannabinoid system in neuroinflammation”. Frontiers in Pharmacology 12 (2022): 806417.
  33. Limongi D and S Baldelli. “Redox imbalance and viral infections in neurodegenerative diseases”. Oxidative Medicine and Cellular Longevity (2016): 6547248.
  34. Paloczi J., et al. “Neuroprotection in oxidative stress-related neurodegenerative diseases: role of endocannabinoid system modulation”. Antioxidants and Redox Signaling1 (2018): 75-108.
  35. Hampson A., et al. “Cannabidiol and (−) Δ9-tetrahydrocannabinol are neuroprotective antioxidants”. Proceedings of the National Academy of Sciences14 (1998): 8268-8273.
  36. Molina‐Holgado E and F Molina‐Holgado. “Mending the broken brain: neuroimmune interactions in neurogenesis”. Journal of Neurochemistry5 (2010): 1277-1290.
  37. Chevaleyre V., et al. “Endocannabinoid-mediated synaptic plasticity in the CNS”. Annual Review of Neuroscience 1 (2006): 37-76.
  38. Galve-Roperh I., et al. “The endocannabinoid system and neurogenesis in health and disease”. The Neuroscientist2 (2007): 109-114.
  39. Saluja I., et al. “X11α haploinsufficiency enhances Aβ amyloid deposition in Alzheimer's disease transgenic mice”. Neurobiology of Disease1 (2009): 162-168.
  40. Zahid S., et al. “Phosphoproteome profiling of substantia nigra and cortex regions of Alzheimer’s disease patients”. Journal of Neurochemistry6 (2012): 954-963.
  41. Wang PY., et al. “Antitumor and immunomodulatory effects of polysaccharides from broken-spore of Ganoderma lucidum”. Frontiers in Pharmacology 3 (2012): 135.
  42. Lu HC and K Mackie. “An introduction to the endogenous cannabinoid system”. Biological Psychiatry7 (2016): 516-525.
  43. Di Marzo V. “New approaches and challenges to targeting the endocannabinoid system”. Nature Reviews Drug Discovery9 (2018): 623-639.
  44. Russo EB. “Cannabinoids in the management of difficult to treat pain”. Therapeutics and Clinical Risk Management 1 (2008): 245-259.
  45. Morales P and PH Reggio. “An update on non-CB1, non-CB2 cannabinoid related G-protein-coupled receptors”. Cannabis and Cannabinoid Research1 (2017): 265-273.
  46. Blankman JL and BF Cravatt. “Chemical probes of endocannabinoid metabolism”. Pharmacological Reviews2 (2013): 849-871.
  47. Nomura DK., et al. “Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation”. Science6057 (2011): 809-813.
  48. Ahn K., et al. “Enzymatic pathways that regulate endocannabinoid signaling in the nervous system”. Chemical Reviews5 (2008): 1687-1707.
  49. Hryhorowicz S., et al. “Pharmacogenetics of cannabinoids”. European Journal of Drug Metabolism and Pharmacokinetics1 (2018): 1-12.
  50. Pisanti S., et al. “Cannabidiol: State of the art and new challenges for therapeutic applications”. Pharmacology and Therapeutics 175 (2017): 133-150.
  51. Fernández‐Ruiz J., et al. “Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?” British Journal of Clinical Pharmacology2 (2013): 323-333.
  52. Cassano T., et al. “From Cannabis sativa to cannabidiol: Promising therapeutic candidate for the treatment of neurodegenerative diseases”. Frontiers in Pharmacology 11 (2020): 124.

Nemer Mohammad Ali and Reham Kharmah. “The Role of the Endocannabinoid System in Neuroprotection: Mechanisms and Therapeutic Potential”. EC Neurology  16.9 (2024): 01-07.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net